We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

56 hedge funds and large institutions have $150M invested in Prelude Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 14

32% more capital invested

Capital invested by funds: $113M → $150M (+$36.4M)

0% more call options, than puts

Call options by funds: $4K | Put options by funds: $4K

2.92% less ownership

Funds ownership: 66.8% → 63.88% (-2.9%)

7% less funds holding

Funds holding: 60 → 56 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
56
Holders Change
-4
Holders Change %
-6.67%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
29
Reduced
14
Closed
10
Calls
$4K
Puts
$4K
Net Calls
–
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$12.6M
2
Morgan Stanley
Morgan Stanley
New York
+$1.08M
3
BCM
Bridgeway Capital Management
Texas
+$340K
4
Renaissance Technologies
Renaissance Technologies
New York
+$234K
5
BC
Boxer Capital
California
+$223K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$14.8M
2
EC
EcoR1 Capital
California
-$3.58M
3
Citadel Advisors
Citadel Advisors
Florida
-$623K
4
WP
Woodline Partners
California
-$618K
5
GCP
GSA Capital Partners
United Kingdom
-$218K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$46.6M – – –
BBA
2
Baker Bros. Advisors
New York
$43.2M – – –
DM
3
Deerfield Management
New York
$17.6M +$12.6M +4,133,000 New
BC
4
Boxer Capital
California
$11M +$223K +73,269 +3%
BlackRock
5
BlackRock
New York
$4.68M +$82.7K +27,155 +3%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$4.45M -$73.4K -24,121 -2%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.3M +$101K +33,250 +3%
Morgan Stanley
8
Morgan Stanley
New York
$2.55M +$1.08M +353,122 +144%
Massachusetts Financial Services
9
Massachusetts Financial Services
Massachusetts
$2.18M +$1.43K +470 +0.1%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.49M +$55.6K +18,267 +6%
SCM
11
Sio Capital Management
New York
$1.37M -$90.1K -29,606 -8%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$1.13M -$14.8M -4,866,746 -95%
Renaissance Technologies
13
Renaissance Technologies
New York
$924K +$234K +77,026 +55%
State Street
14
State Street
Massachusetts
$906K +$76.2K +25,025 +13%
TD Asset Management
15
TD Asset Management
Ontario, Canada
$686K – – –
BCM
16
Bridgeway Capital Management
Texas
$635K +$340K +111,800 +303%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$561K -$38.5K -12,650 -9%
Charles Schwab
18
Charles Schwab
California
$532K +$5.08K +1,669 +1%
Northern Trust
19
Northern Trust
Illinois
$487K -$4.33K -1,421 -1%
Millennium Management
20
Millennium Management
New York
$414K +$101K +33,099 +52%
Citadel Advisors
21
Citadel Advisors
Florida
$407K -$623K -204,771 -68%
Manulife (Manufacturers Life Insurance)
22
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$300K – – –
Goldman Sachs
23
Goldman Sachs
New York
$297K +$5.41K +1,777 +3%
PFCS
24
Pale Fire Capital SE
Czech Republic
$271K +$99.9K +32,800 +107%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$264K +$93.5K +30,700 +99%
1
2 3

PRLD Hedge Fund Activity: Q4 2023 in Review

56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2023, worth a combined $150M — up 32% from $113M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of PRLD and 6 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 29 added.

The largest buyer was Deerfield Management, opening a new position worth an estimated $12.6M. The largest seller was Fidelity Investments, cutting an estimated $14.8M.

  • 56 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2023, down from 60 in Q3 2023.
  • Funds reported $150M of Prelude Therapeutics stock for Q4 2023, up 32% quarter-over-quarter.
  • 6 funds opened new Prelude Therapeutics positions in Q4 2023 and 10 closed out, a net change of -4 holders.
  • The largest Prelude Therapeutics buyer in Q4 2023 was Deerfield Management, an estimated $12.6M added.
  • The largest Prelude Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $14.8M sold.

Based on aggregated 13F filings for Q4 2023.